share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A：重大事件(修正)
美股SEC公告 ·  2024/08/09 05:05

Moomoo AI 已提取核心信息

Ginkgo Bioworks reported Q2 2024 revenue of $56 million, down 30% YoY, with Cell Engineering revenue declining 20% to $36 million and Biosecurity revenue at $20 million. The quarter's operating loss was $223 million, including $38 million in stock-based compensation and $72 million in restructuring costs.The company has begun implementing its previously announced restructuring plan, with workforce reductions starting in June 2024 expected to achieve over $85 million in annualized savings by mid-2025. The plan includes consolidating office and laboratory operations into fewer locations, with facility consolidation actions targeted for completion in 2025.Despite restructuring, Ginkgo maintained its 2024 revenue guidance of $170-190 million, including $120-140 million from Cell Engineering and at least $50 million from Biosecurity. The company added 18 new programs in Q2, including its first Lab Data as a Service deals with a large tech company, while maintaining $730 million in cash and cash equivalents.
Ginkgo Bioworks reported Q2 2024 revenue of $56 million, down 30% YoY, with Cell Engineering revenue declining 20% to $36 million and Biosecurity revenue at $20 million. The quarter's operating loss was $223 million, including $38 million in stock-based compensation and $72 million in restructuring costs.The company has begun implementing its previously announced restructuring plan, with workforce reductions starting in June 2024 expected to achieve over $85 million in annualized savings by mid-2025. The plan includes consolidating office and laboratory operations into fewer locations, with facility consolidation actions targeted for completion in 2025.Despite restructuring, Ginkgo maintained its 2024 revenue guidance of $170-190 million, including $120-140 million from Cell Engineering and at least $50 million from Biosecurity. The company added 18 new programs in Q2, including its first Lab Data as a Service deals with a large tech company, while maintaining $730 million in cash and cash equivalents.
银杏生物科技报告2024年第二季度营业收入为5600万美元，同比下降30%，电芯工程营业收入下降20%，为3600万美元，生物安全营业收入为2000万美元。该季度的运营亏损为22300万美元，包括3800万美元的股票薪酬和7200万美元的重组费用。该公司已经开始实施其先前宣布的重组计划，预计从2024年6月开始的员工裁减将于2025年中期实现超过8500万美元的年度节省。该计划包括将办公室和实验室的运营整合到更少的地点，设施整合措施预计在2025年完成。尽管进行了重组，银杏仍然维持其2024年的营业收入指导在17000-19000万美元，其中电芯工程预计收入在12000-14000万美元，生物安全至少5000万美元。该公司在第二季度增加了18个新项目，包括与一家大型科技公司的首个实验室数据即服务协议，同时保持了73000万美元的现金及现金等价物。
银杏生物科技报告2024年第二季度营业收入为5600万美元，同比下降30%，电芯工程营业收入下降20%，为3600万美元，生物安全营业收入为2000万美元。该季度的运营亏损为22300万美元，包括3800万美元的股票薪酬和7200万美元的重组费用。该公司已经开始实施其先前宣布的重组计划，预计从2024年6月开始的员工裁减将于2025年中期实现超过8500万美元的年度节省。该计划包括将办公室和实验室的运营整合到更少的地点，设施整合措施预计在2025年完成。尽管进行了重组，银杏仍然维持其2024年的营业收入指导在17000-19000万美元，其中电芯工程预计收入在12000-14000万美元，生物安全至少5000万美元。该公司在第二季度增加了18个新项目，包括与一家大型科技公司的首个实验室数据即服务协议，同时保持了73000万美元的现金及现金等价物。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Channel Therapeutics
    CHRO
    -- 1.900
    泰坦制药
    TTNP
    -- 3.8350
    LakeShore Biopharma
    LSB
    -- 2.723
    Rigel Pharmaceuticals
    RIGL
    -- 20.130
    Veru Inc
    VERU
    -- 0.975

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    ▪️加密货币政策能否利好crypto？ ▪️关税政策能否利好中概等海外资产？ 展开
    特朗普2.0机会预览：在总统上任前猜出市场赢家！